Table 2 Demographic data of children with CHD who received immunoprophylaxis with palivizumab at the FHCGV from January to June 2016, in Belém, Pará, Brazil
Characteristics | n | % |
|---|---|---|
Gender | ||
Male | 60 | 57.7 |
Female | 44 | 42.3 |
Geographic origin | ||
Belém | 30 | 28.8 |
Belém metropolitan area | 18 | 17.3 |
Countryside | 56 | 53.9 |
Hospital sector of origin | ||
Outpatient clinics | 84 | 80.8 |
Esternal outpatient clinics | 3 | 2.9 |
Paeditrics clinics | 11 | 10.5 |
Neonate ICU | 6 | 5.8 |
Month of the beginning of immunoprophylaxis | ||
January | 33 | 31.7 |
February | 27 | 26.0 |
March | 20 | 19.2 |
April | 10 | 9.6 |
May | 10 | 9.6 |
June | 4 | 3.8 |
Number of palivizumab doses taken | ||
1 dose | 16 | 15.4 |
2 doses | 24 | 23.1 |
3 doses | 15 | 14.4 |
4 doses | 13 | 12.5 |
5 doses | 19 | 18.3 |
6 doses | 17 | 16.3 |